Yoni Freedhoff, MD DISCLOSURES | December 06, 2024 143993 Added to Email Alert They’re literally not better. Idealistically, sure, but literally not. And there’s really no debate. Meaning there’s never been a reproducible diet and exercise intervention that has led to anywhere near the average weight lost by those taking obesity medications. Furthermore, when it comes to the durability...
Tag: <span>Obesity drug</span>
Post
Experimental obesity drug packs double punch to reduce weight
Test of weight-loss candidate in mice shows that there is still room for improvement in a burgeoning field. By Asher Mullard Researchers adapted a peptide similar to the one used in the obesity drug Wegovy to have an even more potent weight-loss response in mice.Credit: Lise Aaserud/NTB/Alamy With obesity drugs now helping people to slim...
Post
Navigating the Semaglutide Shortage: How Doctors Manage Obesity Drug Challenges With Patients
The semaglutide shortage probably won’t last forever. But for now, physicians strive to provide the best care for their patients as they navigate the shortage as part of a crucial aspect of their practice. But even when drug manufacturers like Novo Nordisk straighten out supply chain issues and the obesity drug Wegovy, for instance, becomes...
Post
Lilly’s Mounjaro Leads to More and Faster Weight Loss Than Novo Obesity Drug, Data Analysis Finds
By Nancy Lapid (Reuters) – Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly’s Mounjaro than those taking Novo Nordisk’s popular rival weight loss drug, according to an analysis of health records and other data. Within one year of starting treatment, 42.3% of those taking tirzepatide – the active ingredient...
Post
Obesity drug brings heart health benefit alongside weight loss, study says
By Jennifer Rigby, Reuters | Posted – May 21, 2023 at 8:02 p.m. DUBLIN — Taking Novo Nordisk’s new obesity drug may help reduce the risk of heart disease as well as boosting weight loss, according to new research from the United States. After a year of taking semaglutide, marketed as Wegovy, patients’ risk of...
Post
Study shows game-changing obesity drug more than halves risk of type 2 diabetes
DIABETOLOGIA The risk of type 2 diabetes (T2D) is more than halved by weekly injections of new obesity drug semaglutide, according to new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden (19-23 Sept). Semaglutide was recently approved in the US as an obesity...
Post
Newly Discovered Brain Response to Obesity Drug May Inform Future Treatments
The U.S. Food and Drug Administration-approved drug liraglutide have been shown to help obese patients lose weight by suppressing their appetite. However, where and how the drug acts in the brain was not fully understood, until now. A new preclinical study from the Perelman School of Medicine at the University of Pennsylvania, published in Science...
Post
Researchers discover experimental obesity drug prevents development of kidney stones
Copenhagen: Scientists have found that a drug connected with fat regulation prevents the formation of kidney stones in mice. This early work opens the possibility of developing drugs which may help prevent kidney stones in at-risk individuals. The work is presented at the European Association of Urology Conference in Copenhagen. Passing a kidney stone in...